X0306 4 2014-12-12 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001242825 LEIDEN JEFFREY M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 1 0 0 CEO & President Common Stock 2014-12-12 4 G 0 2500 0.00 D 267694 D Common Stock 2014-12-15 4 S 0 13021 113.19 D 254673 D Common Stock 2014-12-15 4 S 0 15440 114.21 D 239233 D Common Stock 2014-12-15 4 S 0 6406 115.05 D 232827 D Common Stock 2014-12-15 4 S 0 3400 116.27 D 229427 D Common Stock 2014-12-15 4 S 0 8650 117.26 D 220777 D Common Stock 2014-12-15 4 S 0 2700 118.05 D 218077 D Common Stock 2014-12-15 4 S 0 200 119.00 D 217877 D Common Stock 2014-12-15 4 S 0 200 120.17 D 217677 D Common Stock 440 I 401(k) Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Represents a gift made to a charitable donor-advised fund. Open market sales reported on this line occurred at a weighted average price of $113.19 (range $112.66 to $113.65). Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $114.21 (range $113.66 to $114.65). Open market sales reported on this line occurred at a weighted average price of $115.05 (range $114.69 to $115.68). Open market sales reported on this line occurred at a weighted average price of $116.27 (range $115.73 to $116.70). Open market sales reported on this line occurred at a weighted average price of $117.26 (range $116.74 to $117.73). Open market sales reported on this line occurred at a weighted average price of $118.05 (range $117.74 to $118.64). Kenneth L. Horton, Attorney-In-Fact 2014-12-16